Danske Bank’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.3M Buy
72,275
+5,910
+9% +$1.25M 0.03% 359
2026
Q2
$14.3M Buy
66,365
+18,948
+40% +$3.62M 0.03% 385
2026
Q1
$8.69M Sell
47,417
-998
-2% -$184K 0.02% 458
2025
Q4
$8.52M Buy
48,415
+3,705
+8% +$605K 0.02% 470
2025
Q3
$6.26M Sell
44,710
-10,686
-19% -$1.44M 0.02% 507
2025
Q2
$6.96M Sell
55,396
-8,532
-13% -$1.06M 0.02% 485
2025
Q1
$8.75M Sell
63,928
-15,870
-20% -$2.27M 0.03% 432
2024
Q4
$12.2M Buy
79,798
+14,114
+21% +$2.38M 0.04% 378
2024
Q3
$12.7M Buy
65,684
+253
+0.4% +$52.9K 0.04% 341
2024
Q2
$15.2M Sell
65,431
-18,423
-22% -$4M 0.06% 287
2024
Q1
$18.1M Buy
+83,854
New +$19.6M 0.06% 295

Other funds holding BIIB

Danske Bank's BIIB Position: Q3 2026 in Review

Danske Bank increased its Biogen (BIIB) stake by 8.9% in Q3 2026, buying an estimated $1.25M and bringing the position to 72,275 shares worth $16.3M. The position accounts for 0.03% of the portfolio, ranked #359.

Danske Bank first reported a position in BIIB in Q1 2024 and has held it in 11 quarters since. The position peaked at $18.1M in Q1 2024. 1,062 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

  • Danske Bank held 72,275 shares of Biogen worth $16.3M as of Q3 2026.
  • Danske Bank bought 5,910 Biogen shares in Q3 2026, an estimated $1.25M.
  • Biogen made up 0.03% of Danske Bank's portfolio in Q3 2026, its #359 holding.
  • Danske Bank first reported a position in Biogen in Q1 2024 and has held it in 11 quarters since.
  • Danske Bank's Biogen position peaked at $18.1M in Q1 2024.
  • 1,062 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on Danske Bank's 13F filing for Q3 2026, filed 9 Nov 2026.